Merrill maintains Onyx at neutral

Onyx Pharmaceuticals, Inc. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating. The company's Nexavar was approved with a broader-than-expected label and 60% higher-than-expected pricing. Merrill said it raised sales estimates, but low visibility on co-promotion expenses and uncertainty about Pfizer's competitive drug Sutent has caused it to remain neutral for now. Shares of the Emeryville, Calif., biopharmaceutical company were down 30 cents, or 1.03%, at $28.85 on volume of 4,331,824 shares versus the three-month running average of 1,029,470 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.